Innovus Pharmaceuticals, Inc. (INNV: OTCQB) | Innovus Pharma Expands its Executive Management Team with the Addition of Randy Berholtz as its Executive Vice President, Corporate Development and General Counsel

OTC

Innovus Pharma Expands its Executive Management Team with the Addition of Randy Berholtz as its Executive Vice President, Corporate Development and General Counsel

Jan 06, 2017

OTC Disclosure News Service

Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB Venture Market:
INNV), an emerging commercial stage pharmaceutical company that delivers
safe, innovative and effective over-the-counter medicine and consumer
care products to improve men’s and women’s health and respiratory
diseases, today announced that Randy Berholtz will join the management
team as Executive Vice President, Corporate Development and General
Counsel effective January 9, 2017. A life sciences business and legal
veteran with decades of experience, Berholtz joins Innovus Pharma to
expand its corporate development efforts to find and enter into
additional collaborations to expand the breadth and depth of product
offerings on a worldwide basis.

“I am very excited to bring on Randy at this important period of
commercial growth for Innovus Pharma,” said Dr. Bassam Damaj, Innovus’
Chief Executive Officer. “His business, legal and deal-making expertise
and experience will help us to increase our capacity to find, negotiate
with and enter into additional acquisitions and partnerships that will
help us increase our product offerings and expand our international
commercialization efforts to take our company to the next stage.”

“I am very excited to be joining the Innovus Pharma executive team at
this important point in the Company’s growth,” said Berholtz. “I look
forward to working with Bassam, Robert Hoffman and the entire Innovus
Pharma team on growing the Company’s product portfolio, expanding its
corporate partnerships and increasing its revenues.”

Berholtz will oversee Innovus Pharma’s corporate development, business
development and legal areas.

Mr. Berholtz was recently the founding partner of the Sorrento Valley
Law Group, a healthcare and life sciences law firm and had previously
been a part-time consultant for the Company from July 2013 to mid-May
2016. Previously, from 2011 to 2013, he was the Executive Vice
President, General Counsel and Secretary of Apricus Biosciences, Inc., a
biotechnology company (Nasdaq:APRI); from 2004 to 2010, he was the Vice
President, General Counsel and Secretary of the ACON Group of private
U.S. and Chinese life science companies; from 2003 to 2004, he was the
Chief Operating Officer and General Counsel to Inglewood Ventures, a
life sciences venture capital firm; and from 2000 to 2003, he held
multiple titles and rose to become the Acting General Counsel and
Secretary of Nanogen, Inc., a genomics tools company (Nasdaq:NGEN). From
1992 to 2000, Mr. Berholtz was in private practice with law firms in New
York and San Diego and from 1990 to 1991, he was a law clerk to Judge
Jerry E. Smith on the U.S. Court of Appeals for the Fifth Circuit.

Mr. Berholtz is a member of the board of directors of Hispanica
International Delights of America, Inc., an ethnic food company
(OTC:HISP) and Larada Health, Inc., a private company in the medical
supply business and is a Senior Advisor to Mesa Verde Ventures, a life
sciences venture capital firm. Mr. Berholtz received his B.A. from
Cornell University, his M.Litt. from Oxford University where he was a
Rhodes Scholar, his J.D. from Yale University and his M.B.A. from the
University of San Diego.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging commercial
stage pharmaceutical company delivering over-the-counter medicines and
consumer care products for men’s and women’s health and respiratory
diseases. The Company generates revenues from its lead products (a) BTH®
Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for
female arousal and (d) EjectDelay® for premature ejaculation and has an
additional five marketed products in this space, including (e) Sensum+®
to help with reduced penile sensitivity, (f) Zestra Glide®, (g) Vesele®
for promoting sexual health, (h) RecalMax™ for promoting brain and
cognitive health, (i) Androferti® (in the US and Canada) to support
overall male reproductive health and sperm quality, (j) BTH Vision
Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC
for allergic rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to www.innovuspharma.com,
www.zestra.com;
www.ejectdelay.com;
www.myvesele.com;
www.sensumplus.com;
www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com;
www.trybeyondhuman.com;
www.recalmax.com;
www.urivarx.com.

Innovus Pharma’s Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, additional acquisitions, commercial partnerships, and to achieve its
other development, growth, commercialization, financial and staffing
objectives. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially
from the forward-looking statements contained herein. Readers are urged
to read the risk factors set forth in the Company’s most recent annual
report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and
other filings made with the SEC. Copies of these reports are available
from the SEC’s website or without charge from the Company.

Copyright © 2017 Businesswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Leave a Reply